Ras genes code for small membrane-bound proteins (p21’ı) that bind and hydrolyze GTP. They participate, through a cascade of protein kinases, in transmitting signals into the nucleus. Activating point mutations, in genes of the ras gene family, that convert these proto-oncogenes into their transforming forms are well documented to occur in many human tumours. Mutations in the critical codons 12, 13 and 61 activate the oncoprotein and lead to oncogenic transformation.
The assay is for the detection of point mutations in the Ras gene in codons 12, 13 and 61 in patients with solid tumours.
Patients with a mutation in KRAS/NRAS may not respond to treatment with anti EGFR Antibody therapy. KRAS/NRAS mutations potentially confers lack of response to anti EGFR-antibody therapy in Colorectal cancer.
Synonyms or keywords:
Colorectal cancer, anti EGFR-antibody therapy and c-Ki-ras-2 (K-ras) oncogene.